Multicenter survey of the efficacy and compliance with using topical pimecrolimus by patients with atopic dermatitis

Beom Joon Kim, Myeung Nam Kim, Kyu Han Kim, Do Won Kim, Young Suck Ro, Chun Wook Park, Seung Chul Lee, Ai Young Lee, Jee Ho Choi, Kwang Hoon Lee

Research output: Contribution to journalArticle

Abstract

Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that's influenced by many genetic and environmental factors. Various treatment modalities are being applied for AD, including phototherapy, topical applicants and systemic agents. However, there has been no mass survey in Korea concerning the compliance of patients' to use their prescribed medication, which might influence the clinical efficacy of the physicians' treatment. Objective: The purpose of the present study is to evaluate the efficacy, safety and patient compliance with using topical pimecrolimus to treat AD. Methods: We reviewed the medical recordings, laboratory profiles, clinical severity scoring and photographs of AD patients at 9 general hospitals in Seoul and the local area of Korea. Interviews with the patients and a telephone survey were also done. Those patients who weren't perscribed topical applicants or those who did not use topical pimecrolimus or steroid within 6 months were excluded from this study. Results: Topical pimecrolimus cream effectively controlled AD with a reduction of the EASI score from baseline 13.75 to 11.39 at 2 weeks and 4.46 at 10 weeks of topical pimecrolimus application. When topical pimecrolimus cream was applied for more than 12 months it significandy suppressed the recurrence and reactivation of AD (p<0.05). Although 22.6% of the patients complained of adverse effects, these were all transient and they did not evoke significant medical problems. Using topical pimecrolimus cream did not show significant adverse effects or complications. Conclusion: Topical pimecrolimus might well be an effective treatment modality for treating AD when patients show good compliance for applying the cream. (Korean J Dermatol 2008;46(10):1357-1361).

Original languageEnglish
Pages (from-to)1357-1361
Number of pages5
JournalKorean Journal of Dermatology
Volume46
Issue number10
Publication statusPublished - 2008 Oct 1

Fingerprint

Atopic Dermatitis
Patient Compliance
Korea
Phototherapy
pimecrolimus
Surveys and Questionnaires
Skin Diseases
Telephone
General Hospitals
Therapeutics
Steroids
Interviews
Physicians
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Kim, Beom Joon ; Kim, Myeung Nam ; Kim, Kyu Han ; Kim, Do Won ; Ro, Young Suck ; Park, Chun Wook ; Lee, Seung Chul ; Lee, Ai Young ; Choi, Jee Ho ; Lee, Kwang Hoon. / Multicenter survey of the efficacy and compliance with using topical pimecrolimus by patients with atopic dermatitis. In: Korean Journal of Dermatology. 2008 ; Vol. 46, No. 10. pp. 1357-1361.
@article{edafadbb97914c5e83f7296f61103230,
title = "Multicenter survey of the efficacy and compliance with using topical pimecrolimus by patients with atopic dermatitis",
abstract = "Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that's influenced by many genetic and environmental factors. Various treatment modalities are being applied for AD, including phototherapy, topical applicants and systemic agents. However, there has been no mass survey in Korea concerning the compliance of patients' to use their prescribed medication, which might influence the clinical efficacy of the physicians' treatment. Objective: The purpose of the present study is to evaluate the efficacy, safety and patient compliance with using topical pimecrolimus to treat AD. Methods: We reviewed the medical recordings, laboratory profiles, clinical severity scoring and photographs of AD patients at 9 general hospitals in Seoul and the local area of Korea. Interviews with the patients and a telephone survey were also done. Those patients who weren't perscribed topical applicants or those who did not use topical pimecrolimus or steroid within 6 months were excluded from this study. Results: Topical pimecrolimus cream effectively controlled AD with a reduction of the EASI score from baseline 13.75 to 11.39 at 2 weeks and 4.46 at 10 weeks of topical pimecrolimus application. When topical pimecrolimus cream was applied for more than 12 months it significandy suppressed the recurrence and reactivation of AD (p<0.05). Although 22.6{\%} of the patients complained of adverse effects, these were all transient and they did not evoke significant medical problems. Using topical pimecrolimus cream did not show significant adverse effects or complications. Conclusion: Topical pimecrolimus might well be an effective treatment modality for treating AD when patients show good compliance for applying the cream. (Korean J Dermatol 2008;46(10):1357-1361).",
author = "Kim, {Beom Joon} and Kim, {Myeung Nam} and Kim, {Kyu Han} and Kim, {Do Won} and Ro, {Young Suck} and Park, {Chun Wook} and Lee, {Seung Chul} and Lee, {Ai Young} and Choi, {Jee Ho} and Lee, {Kwang Hoon}",
year = "2008",
month = "10",
day = "1",
language = "English",
volume = "46",
pages = "1357--1361",
journal = "Korean Journal of Dermatology",
issn = "0494-4739",
publisher = "Korean Dermatological Association",
number = "10",

}

Kim, BJ, Kim, MN, Kim, KH, Kim, DW, Ro, YS, Park, CW, Lee, SC, Lee, AY, Choi, JH & Lee, KH 2008, 'Multicenter survey of the efficacy and compliance with using topical pimecrolimus by patients with atopic dermatitis', Korean Journal of Dermatology, vol. 46, no. 10, pp. 1357-1361.

Multicenter survey of the efficacy and compliance with using topical pimecrolimus by patients with atopic dermatitis. / Kim, Beom Joon; Kim, Myeung Nam; Kim, Kyu Han; Kim, Do Won; Ro, Young Suck; Park, Chun Wook; Lee, Seung Chul; Lee, Ai Young; Choi, Jee Ho; Lee, Kwang Hoon.

In: Korean Journal of Dermatology, Vol. 46, No. 10, 01.10.2008, p. 1357-1361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multicenter survey of the efficacy and compliance with using topical pimecrolimus by patients with atopic dermatitis

AU - Kim, Beom Joon

AU - Kim, Myeung Nam

AU - Kim, Kyu Han

AU - Kim, Do Won

AU - Ro, Young Suck

AU - Park, Chun Wook

AU - Lee, Seung Chul

AU - Lee, Ai Young

AU - Choi, Jee Ho

AU - Lee, Kwang Hoon

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that's influenced by many genetic and environmental factors. Various treatment modalities are being applied for AD, including phototherapy, topical applicants and systemic agents. However, there has been no mass survey in Korea concerning the compliance of patients' to use their prescribed medication, which might influence the clinical efficacy of the physicians' treatment. Objective: The purpose of the present study is to evaluate the efficacy, safety and patient compliance with using topical pimecrolimus to treat AD. Methods: We reviewed the medical recordings, laboratory profiles, clinical severity scoring and photographs of AD patients at 9 general hospitals in Seoul and the local area of Korea. Interviews with the patients and a telephone survey were also done. Those patients who weren't perscribed topical applicants or those who did not use topical pimecrolimus or steroid within 6 months were excluded from this study. Results: Topical pimecrolimus cream effectively controlled AD with a reduction of the EASI score from baseline 13.75 to 11.39 at 2 weeks and 4.46 at 10 weeks of topical pimecrolimus application. When topical pimecrolimus cream was applied for more than 12 months it significandy suppressed the recurrence and reactivation of AD (p<0.05). Although 22.6% of the patients complained of adverse effects, these were all transient and they did not evoke significant medical problems. Using topical pimecrolimus cream did not show significant adverse effects or complications. Conclusion: Topical pimecrolimus might well be an effective treatment modality for treating AD when patients show good compliance for applying the cream. (Korean J Dermatol 2008;46(10):1357-1361).

AB - Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that's influenced by many genetic and environmental factors. Various treatment modalities are being applied for AD, including phototherapy, topical applicants and systemic agents. However, there has been no mass survey in Korea concerning the compliance of patients' to use their prescribed medication, which might influence the clinical efficacy of the physicians' treatment. Objective: The purpose of the present study is to evaluate the efficacy, safety and patient compliance with using topical pimecrolimus to treat AD. Methods: We reviewed the medical recordings, laboratory profiles, clinical severity scoring and photographs of AD patients at 9 general hospitals in Seoul and the local area of Korea. Interviews with the patients and a telephone survey were also done. Those patients who weren't perscribed topical applicants or those who did not use topical pimecrolimus or steroid within 6 months were excluded from this study. Results: Topical pimecrolimus cream effectively controlled AD with a reduction of the EASI score from baseline 13.75 to 11.39 at 2 weeks and 4.46 at 10 weeks of topical pimecrolimus application. When topical pimecrolimus cream was applied for more than 12 months it significandy suppressed the recurrence and reactivation of AD (p<0.05). Although 22.6% of the patients complained of adverse effects, these were all transient and they did not evoke significant medical problems. Using topical pimecrolimus cream did not show significant adverse effects or complications. Conclusion: Topical pimecrolimus might well be an effective treatment modality for treating AD when patients show good compliance for applying the cream. (Korean J Dermatol 2008;46(10):1357-1361).

UR - http://www.scopus.com/inward/record.url?scp=58849147129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849147129&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:58849147129

VL - 46

SP - 1357

EP - 1361

JO - Korean Journal of Dermatology

JF - Korean Journal of Dermatology

SN - 0494-4739

IS - 10

ER -